{"disease":{"id":"initial-insomnia","name":"Initial insomnia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"zolpidem","indication_name":"Initial insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ambien","generic_name":"zolpidem","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"α1 subunit containing GABA A receptors","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Zolpidem binds to the benzodiazepine site of α1 subunit containing GABA A receptors, increasing chloride channel opening and inhibiting neuronal excitation."},{"drug_id":"ramelteon","indication_name":"Initial insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rozerem","generic_name":"RAMELTEON","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Melatonin receptor type 1A","drug_class":"Melatonin Receptor Agonist [EPC]","quality_score":70,"revenue":null,"mechanism":"Rozerem works by activating the melatonin receptor type 1A to regulate sleep-wake cycles."},{"drug_id":"zaleplon","indication_name":"Initial insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sonata","generic_name":"ZALEPLON","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"gamma-Aminobutyric Acid A Receptor Agonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"rozerem","indication_name":"Initial insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rozerem","company_name":"Northwestern University","drug_phase":"marketed","molecular_target":"Melatonin receptor type 1A, Melatonin receptor type 1B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02333149","title":"Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Alberta","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}